Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Paediatric Joint Formulary
Home > Formulary : Paediatric > Recent Decisions > 2023 >

Decisions 17th October 2023

New Drug Requests:  

Approved

Actimorph (morphine sulfate orodispersible tablets) (TLS Amber Specialist Recommended)

  • pain relief 

Aklief® (trifarotene cream 50micrograms/g) (TLS Green)

  • treatment of acne 

Other decisions and discussions:

  • Morphine TLS changed from Green to Amber Specialist Recommended
  • Tramadol TLS changed from Green to Amber Specialist Recommended
  • Folinic acid (calcium folinate) for metabolic disorders - TLS changed from Red to Amber Specialist Recommended
  • ADHD SCPs for methylphenidate, lisdexamfetamine and atomoxetine approved
  • Ketorolac injection - TLS to change to Red on all formulary chapters.
  • ADHD medicines shortage discussed. 
  • Adex gel emollient - not approved for treatment of eczema, psoriasis and dermatitis.
  • Doublebase Once emollient - not approved for treatment of eczema, psoriasis and dermatitis.

 

Cardiovascular Chapter Review and Update

Decisions include:

  • Lipid lowering drugs - TLS to change to Amber Specialist Initiated for some lipid lowering drugs
  • Enoxaparin - TLS to be changed to Red for all patients
  • Nadalol, propranolol, carvedilol, metoprolol, nadolol, atenolol, amlodipine, nifedipine, diltiazem, verapamil, captopril, enalapril, lisinopril,losartan, irbesartan,spironolactone,furosemide- change TLS to Amber Specialist Initiated
  • Hydralazine, sotalol, verapamil, - change TLS to Amber 1 month when a SCP has been developed and approved
  • Taurolock, alteplase and streptokinase to be added as TLS Red
  • Adrenaline and noradrenaline to be added as TLS Red (inotrope for Heart Failure)
  • valsartan- remove (not used)
  • Digoxin, aspirin, warfarin, flecainide, -TLS to change Amber Specialist Initiated 
  • Clopidogrel- further work needed